Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buventol Easyhaler is a branded dry powder inhaler formulation of salbutamol (albuterol) sulfate, a short-acting selective beta2-adrenergic receptor agonist used as a rapid-acting bronchodilator for the relief and prevention of acute bronchospasm in asthma, exercise-induced bronchospasm, and chronic obstructive pulmonary disease with reversible airway obstruction.[1][7][17] By selectively stimulating beta2 receptors in bronchial smooth muscle, salbutamol activates adenylyl cyclase, increases intracellular cAMP, and promotes relaxation of airway smooth muscle, leading to prompt bronchodilation within minutes and a duration of action of about 4–6 hours.[1][2] Buventol Easyhaler is intended as a “reliever” or rescue medication rather than long-term controller therapy, and is marketed in multiple regions by Orion and its partners for on-demand symptomatic treatment and prophylaxis before exercise.[1][5][8][11][13][17]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Buventol Easyhaler.